While the Neurofoundational Model was designed to conceptualize NfL’s role specifically in MS, we acknowledge that elevated NfL levels are also observed in other progressive neurological disorders, such as Alzheimer’s disease, ALS, and Parkinson’s disease. This evidence concerns the gene NEFL and myeloid sarcoma.